Premium
An ER‐Targeting Iridium(III) Complex That Induces Immunogenic Cell Death in Non‐Small‐Cell Lung Cancer
Author(s) -
Wang Lili,
Guan Ruilin,
Xie Lina,
Liao Xinxing,
Xiong Kai,
Rees Thomas W.,
Chen Yu,
Ji Liangnian,
Chao Hui
Publication year - 2021
Publication title -
angewandte chemie
Language(s) - English
Resource type - Journals
eISSN - 1521-3757
pISSN - 0044-8249
DOI - 10.1002/ange.202013987
Subject(s) - immunogenic cell death , calreticulin , endoplasmic reticulum , cancer research , programmed cell death , cell , chemistry , cd8 , microbiology and biotechnology , apoptosis , biology , immunology , antigen , biochemistry
Immunogenic cell death (ICD) is a vital component of therapeutically induced anti‐tumor immunity. An iridium(III) complex ( Ir1 ), containing an N , N ‐bis(2‐chloroethyl)‐azane derivate, as an endoplasmic reticulum‐localized ICD inducer for non‐small cell lung cancer (NSCLC) is reported. The characteristic discharge of damage‐associated molecular patterns (DAMPs), that is, cell surface exposure of calreticulin (CRT), extracellular exclusion of high mobility group box 1 (HMGB1), and ATP, were generated by Ir1 in A549 lung cancer cells, accompanied by an increase in endoplasmic reticulum stress and reactive oxygen species (ROS). The vaccination of immunocompetent mice with Ir1 ‐treated dying cells elicited an antitumor CD8 + T cell response and Foxp3 + T cell depletion, which eventually resulted in long‐acting anti‐tumor immunity by the activation of ICD in lung cancer cells. Ir1 is the first Ir‐based complex that is capable of developing an immunomodulatory response by immunogenic cell death.